For example, at a 37% Federal income tax rate, someone making the maximum family contribution of $8,550 to their HSA in 2025 would save over $3,000 in Federal income taxes alone
The observed reduction in HbA1c confirms the expected glycemic benefit of GLP-1 agonists, consistent with previous large-scale trials [16]
Research shows these effects make the compound a useful tool for muscle recovery and metabolic adaptation studies
The finding that a long-acting GIP receptor agonist (LAGIPRA) increases insulin sensitivity by promoting glucose capture in WAT confirms this
Individuals with any of the following conditions should consult with their healthcare provider before use and may not be eligible for treatment: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Known hypersensitivity to GLP-1 or GLP-1/GIP medications or any formulation components, including additives such as vitamin B12 or cobalt Pregnancy or plans to become pregnant (therapy should be discontinued at least two months prior to planned pregnancy) Diabetic ketoacidosis (DKA) or type 1 diabetes Severe gastrointestinal disease (including gastroparesis or active inflammatory bowel disease) Severe cardiovascular disease (including unstable coronary artery disease or heart failure) Recent bariatric or gastrointestinal surgery within the past six months Active cancer currently undergoing chemotherapy or radiation treatment This list is not comprehensive
Here's what the safety risks are potentially with it, and here's what we could do that's probably going to do the same thing, if not better, but in a safer way, with more predictable outcomes. To help other health care providers navigate these conversations, he wrote a review of unapproved peptides for musculoskeletal performance and athletic performance, which was published online earlier this month in the journal Sports Medicine
